S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Undervalued UnitedHealth Group Won’t Be For Long
3 Computer Vision Stocks for Long-Term Gains From AI
DocuSign and The Case for 66% Upside 
Closing prices for crude oil, gold and other commodities
NASDAQ:ELEV

Elevation Oncology (ELEV) Stock Price, News & Analysis

$4.39
-0.04 (-0.90%)
(As of 04/16/2024 ET)
Today's Range
$4.16
$4.53
50-Day Range
$2.56
$5.17
52-Week Range
$0.36
$5.89
Volume
787,850 shs
Average Volume
2.78 million shs
Market Capitalization
$213.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.25

Elevation Oncology MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.1% Upside
$7.25 Price Target
Short Interest
Bearish
12.58% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of Elevation Oncology in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.87) to ($0.78) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars

Medical Sector

613th out of 930 stocks

Biological Products, Except Diagnostic Industry

105th out of 153 stocks

ELEV stock logo

About Elevation Oncology Stock (NASDAQ:ELEV)

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in New York, New York.

ELEV Stock Price History

ELEV Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
All Three of Our Analysts Agree
Elevation Oncology, Inc. Q4 Loss decreases, beats estimates
See More Headlines
Receive ELEV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Elevation Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2024
Today
4/16/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ELEV
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.25
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+67.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-45,700,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.29 per share

Miscellaneous

Free Float
41,402,000
Market Cap
$211.14 million
Optionable
Optionable
Beta
1.34
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. David Dornan Ph.D. (Age 46)
    Chief Scientific Officer
    Comp: $545.5k
  • Ms. Valerie Malyvanh Jansen M.D. (Age 46)
    Ph.D., Chief Medical Officer
    Comp: $641.53k
  • Mr. Joseph J. Ferra Jr. (Age 49)
    CEO, President & Director
    Comp: $391.52k
  • Ms. Tammy Furlong CPA
    P.M.P., CFO & Secretary
  • Mr. Ryan Bloomer
    Head of Tech Ops
  • Candice Masse
    Senior Director of Corporate Communications & Investor Relations
  • Mr. Robert C. Yang
    Vice President of Legal Affairs

ELEV Stock Analysis - Frequently Asked Questions

Should I buy or sell Elevation Oncology stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Elevation Oncology in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELEV shares.
View ELEV analyst ratings
or view top-rated stocks.

What is Elevation Oncology's stock price target for 2024?

5 Wall Street analysts have issued twelve-month price objectives for Elevation Oncology's stock. Their ELEV share price targets range from $6.00 to $8.00. On average, they expect the company's stock price to reach $7.25 in the next year. This suggests a possible upside of 65.1% from the stock's current price.
View analysts price targets for ELEV
or view top-rated stocks among Wall Street analysts.

How have ELEV shares performed in 2024?

Elevation Oncology's stock was trading at $0.5370 on January 1st, 2024. Since then, ELEV shares have increased by 717.5% and is now trading at $4.39.
View the best growth stocks for 2024 here
.

Are investors shorting Elevation Oncology?

Elevation Oncology saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 5,010,000 shares, an increase of 8.2% from the March 15th total of 4,630,000 shares. Based on an average trading volume of 3,060,000 shares, the short-interest ratio is presently 1.6 days. Currently, 12.6% of the company's shares are short sold.
View Elevation Oncology's Short Interest
.

When is Elevation Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ELEV earnings forecast
.

How were Elevation Oncology's earnings last quarter?

Elevation Oncology, Inc. (NASDAQ:ELEV) announced its quarterly earnings data on Wednesday, March, 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02.

When did Elevation Oncology IPO?

Elevation Oncology (ELEV) raised $1 billion in an IPO on Friday, June 25th 2021. The company issued 63,000,000 shares at $15.00-$17.00 per share.

How do I buy shares of Elevation Oncology?

Shares of ELEV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELEV) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners